利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

30 条记录 (耗时 0.026 秒)

    Vitro system for determining formation of A&bgr; amyloid
    4.
    发明授权
    Vitro system for determining formation of A&bgr; amyloid 失效
    用于确定Aβ淀粉样蛋白形成的体外系统

    公开(公告)号：US06365414B1

    公开(公告)日：2002-04-02

    申请号：US08294819

    申请日：1994-08-26

    申请人： Rudolph E. Tanzi ,  Ashley I. Bush

    发明人： Rudolph E. Tanzi ,  Ashley I. Bush

    IPC分类号： G01N2175

    CPC分类号： G01N33/6896 ,  G01N2333/4709 ,  G01N2800/2821 ,  Y10S436/811 ,  Y10T436/25375

    摘要： The invention relates to rapid methods for determining formation of A&bgr; amyloid and screening compounds which inhibit formation of A&bgr; amyloid in vitro, as well as kits for carrying out the present methods. Such an agent used in vivo may prevent, ameliorate or reverse the symptoms of Alzheimer's disease and A&bgr; amyloidotic disorders related to Alzheimer's disease, Down's syndrome, and Guamanian amyotrophic lateral sclerosis/Parkinson's dementia complex. The process described in this invention involves the rapid induction of A&bgr; amyloid by a heavy metal cation capable of binding to a polypeptide comprising at least amino acids 6 to 28 of A&bgr;, such as zinc to form amyloid and determination of formation of tinctorial A&bgr; amyloid. Moreover, a method of determining effectiveness of a candidate anti-amyloidotic agent for prevention or treatment of A&bgr; amyloidosis is described which uses cell cultures which express at least a human A&bgr; peptide.

    摘要翻译： 本发明涉及用于确定Aβ淀粉样蛋白的形成和抑制体外抑制Aβ淀粉样蛋白形成的化合物的快速方法，以及用于实施本发明方法的试剂盒。 在体内使用的这种药剂可以预防，改善或逆转与阿尔茨海默病，唐氏综合征和瓜马尼亚肌萎缩性侧索硬化/帕金森氏综合征相关的阿尔茨海默氏病和阿贝氏淀粉样变性疾病的症状。 本发明描述的方法涉及通过能够与至少包含至少6至28个氨基酸的氨基酸（例如锌）的多肽结合的重金属阳离子快速诱导Aβ淀粉样蛋白，以形成淀粉样蛋白并测定着色的淀粉样蛋白的形成。 此外，描述了确定用于预防或治疗Aβ淀粉样变性的候选抗淀粉样变性剂的有效性的方法，其使用至少表达人Aβ肽的细胞培养物。

    Alpha-2-macroglobulin diagnostic test
    5.
    发明授权
    Alpha-2-macroglobulin diagnostic test 失效
    α-2-巨球蛋白诊断试验

    公开(公告)号：US06342350B1

    公开(公告)日：2002-01-29

    申请号：US09148503

    申请日：1998-09-04

    申请人： Rudolph E. Tanzi ,  Bradley T. Hyman ,  George W. Rebeck ,  Deborah L. Blacker

    发明人： Rudolph E. Tanzi ,  Bradley T. Hyman ,  George W. Rebeck ,  Deborah L. Blacker

    IPC分类号： C12Q168

    CPC分类号： C07K14/8107 ,  C12Q1/6883 ,  C12Q2600/156 ,  C12Q2600/172 ,  G01N33/6896 ,  G01N2800/2821

    摘要： The disclosed invention relates to a diagnostic method for Alzheimer's disease based on genotyping the Alpha-2-Macroglobulin locus. A statistically significant correlation was found between inheritance of particular alleles of the Alpha-2-Macroglobulin gene and the occurrence of Alzheimer's disease. The diagnostic method involves the isolation of nucleic acid from an individual and subsequent genotyping by means such as sequencing or restriction fragment length polymorphism analysis. The invention also provides a means of genotype analysis through protein isotyping Alpha-2-Macroglobulin variant proteins. Finally, kits for nucleic acid analysis or protein analysis are taught.

    摘要翻译： 所公开的发明涉及基于α-2-巨球蛋白基因座的基因分型的阿尔茨海默病的诊断方法。 发现α-2-巨球蛋白基因特异性等位基因遗传与阿尔茨海默病发生之间有统计学意义的相关性。 诊断方法包括通过诸如测序或限制性片段长度多态性分析的方法从个体和随后的基因分型中分离核酸。 本发明还提供通过蛋白质同种型分析α-2-巨球蛋白变体蛋白的基因型分析方法。 最后，教导了用于核酸分析或蛋白质分析的试剂盒。

    REDUCTION OF BETA-AMYLOID LEVELS BY TREATMENT WITH THE SMALL MOLECULE DIFFERENTIATION-INDUCING FACTOR
    8.
    发明申请
    REDUCTION OF BETA-AMYLOID LEVELS BY TREATMENT WITH THE SMALL MOLECULE DIFFERENTIATION-INDUCING FACTOR 审中-公开
    通过用小分子差异诱导因子进行治疗降低β-淀粉样蛋白水平

    公开(公告)号：US20100311726A1

    公开(公告)日：2010-12-09

    申请号：US12669101

    申请日：2008-07-16

    申请人： Michael Myre ,  Wilma Wasco ,  Rudolph E. Tanzi

    发明人： Michael Myre ,  Wilma Wasco ,  Rudolph E. Tanzi

    IPC分类号： A61K31/12 ,  A61K31/445 ,  A61K31/27 ,  A61K31/55 ,  A61K31/4355 ,  A61K31/13 ,  A61K31/498 ,  A61P25/00 ,  A61P25/28

    CPC分类号： A61K31/055

    摘要： The present invention relates to novel uses for a family of small molecules, Differentiation-Inducing Factors (DIFs). It has been discovered that DIFs surprisingly can alter the metabolic processing of amyloid precursor protein (APP) and in turn reduce the level of secreted Aβ. The metabolic processing of other γ-secretase substrates normally present in cells (Notch and APLP1) is not affected when treated with DIF. The invention provides methods for reducing Aβ production in mammalian cells that express APP by administering DIF-I, DIF-2, DIF-3, a functionally equivalent analog and or any combination thereof. The invention also provides methods for treating and/or preventing Alzheimer's disease by preferentially reducing Aβ production.

    摘要翻译： 本发明涉及小分子家族，分化诱导因子（DIF）的新用途。 已经发现DIF令人惊讶地可以改变淀粉样蛋白前体蛋白（APP）的代谢过程，并且反过来降低分泌的A＆bgr的水平。 通常存在于细胞（Notch和APLP1）中的其他γ-分泌酶底物的代谢处理在用DIF处理时不受影响。 本发明提供降低A＆Bgr的方法; 通过施用DIF-1，DIF-2，DIF-3，功能等同的类似物或其任何组合来表达APP的哺乳动物细胞中的产生。 本发明还提供了通过优先降低Aβ作用治疗和/或预防阿尔茨海默氏病的方法。 生产。